Research & Development


  • Ayman AlAbdallah header
    Image attribution tooltip
    Permission granted by Mubadala Capital
    Image attribution tooltip
    Q&A

    In biotech’s new market normal, here’s what’s catching this investor’s eye

    A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation.

    By July 25, 2024
  • An illustration of dollar signs and small pills coming together to make one larger pill, representing a biopharma deal.
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip

    Private biotech M&A surges amid difficult IPO market

    Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups. 

    By Gwendolyn Wu • July 23, 2024
  • clinical trial diversity Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • The HHS in DC
    Image attribution tooltip
    Alex Wong / Staff via Getty Images
    Image attribution tooltip
    Q&A

    Bird flu puts BARDA back in the spotlight

    BARDA director Gary Disbrow explains the agency’s focus, how companies can get their “foot in the door” and why platforms are so important for preparedness.

    By Alexandra Pecci • July 23, 2024
  • dna helix barrier
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    To overcome barriers, cell and gene therapies need outside support

    With great potential in cell and gene therapies, there are still plenty of barriers to getting the breakthroughs to patients.  

    By Kelly Bilodeau • July 22, 2024
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead’s CMO to depart next year

    Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.

    By Ned Pagliarulo • July 19, 2024
  • car t cell
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder

    The pharma company is tackling the “stiff person syndrome” that afflicts Celine Dion in a phase 2 trial for its lead CAR-T candidate.

    By July 19, 2024
  • Dr. Jared Baeten, senior vice president of clinical development, virology therapeutic area head, Gilead
    Image attribution tooltip
    Permission granted by Gilead
    Image attribution tooltip

    Gilead eyes ‘ending the HIV epidemic’ via incremental progress

    With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows that every step counts.

    By July 18, 2024
  • A woman's hands over her abdomen.
    Image attribution tooltip
    Doucefleur via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill

    Ensho Therapeutics just launched but is already generating buzz with its phase 2-ready clinical program for inflammatory bowel disease.

    By Alexandra Pecci • July 17, 2024
  • Amylyx co-ceos
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline

    Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how they’re carrying those lessons forward with other drugs.

    By July 17, 2024
  • Sun coming out
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Has pharma emerged from the ‘age of uncertainty’?

    An industry reeling from a precarious market is showing signs of stabilizing as the future becomes a little less cloudy, an Evaluate report suggests.

    By July 16, 2024
  • virus up close on blue background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Is a better CAR-T cell therapy option on the horizon?

    In vivo CAR-T cell technology has the potential to solve some major issues in the field and could enter the clinic this year.

    By Kelly Bilodeau • July 15, 2024
  • brain on purple AI
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders

    Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and could tee up an IPO.

    By July 15, 2024
  • BMS corporate sign
    Image attribution tooltip
    Courtesy of BMS
    Image attribution tooltip

    BMS’ long-standing leukemia blockbuster stares down its first generic

    Patent disputes in the U.S. and abroad have opened the door to new generics ready for launch as soon as September for BMS’ Sprycel.

    By July 12, 2024
  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer research chief Dolsten to step down, with company at a crossroads

    The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals alongside notable setbacks during his time as Pfizer’s top scientist.

    By Ben Fidler • July 10, 2024
  • Old dog in veterinary clinic.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Could pharma’s blockbuster immunotherapies work in dogs?

    Vetigenics believes it’s found a way to make pricey antibody-based technologies more accessible for animals. 

    By Alexandra Pecci • July 9, 2024
  • VC firms increasingly lean on portfolio companies to report on their diversity, equity, and inclusion (DEI) efforts.
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    The FDA pushes concrete plans to further diversity in clinical trials

    The long-awaited guidance offers a more detailed road map for pharma.

    By Kelly Bilodeau • July 8, 2024
  • David Dodd, CEO, GeoVax
    Image attribution tooltip
    Permission granted by GeoVax
    Image attribution tooltip

    In the rapidly shrinking COVID market, this company still sees opportunity

    GeoVax is developing a next-gen COVID vaccine targeting a population that’s so far been elusive: immunocompromised patients.

    By Alexandra Pecci • July 3, 2024
  • Mehrdad Mobasher, chief medical officer, hematology, BeiGene
    Image attribution tooltip
    Permission granted by BeiGene
    Image attribution tooltip
    Q&A

    How BeiGene is taking on established blockbusters with an expanding blood cancer arsenal

    BeiGene’s Brukinsa is the first in a hematology franchise that the company hopes will rival top-sellers and introduce a new lineup of medicines for patients.

    By July 2, 2024
  • Lovisa Afzelius, co-founder, CEO, Prologue Medicines
    Image attribution tooltip
    Permission granted by Prologue Medicines
    Image attribution tooltip
    Biotech Spotlight

    Protein power: a biotech mining viruses to fight disease

    Flagship Pioneering-backed Prologue Medicine is harnessing the evolutionary tactics of viral proteins to systematically find new drugs.

    By Kelly Bilodeau • July 1, 2024
  • target syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Up-and-comers look for an edge in the bustling ADC field

    The next wave of targeted ADC therapies is on the horizon, and these three potential rising stars could help carry the field forward.

    By June 28, 2024
  • Brain scans
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections

    Neuroscience pipelines are reawakening as biotechs prove to the pharma giants that the field is still worth the investment.

    By June 27, 2024
  • Two prescription drug cartons are seen standing vertically on end, bearing the word Wegovy.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Women with a common hormonal disorder have few good treatment options. Could GLP-1 drugs help?

    Obesity drugs like Wegovy are proving useful in many other diseases. Polycystic ovary syndrome, a chronic condition that can cause infertility, may be one.

    By Delilah Alvarado • June 27, 2024
  • Faye Feller, executive vice president, chief medical officer, Geron
    Image attribution tooltip
    Permission granted by Geron
    Image attribution tooltip

    After 33 years, Geron’s first approval marks a turn in Nobel-winning science

    The decades-long story of how a first-in-class blood cancer treatment went from bench to bedside.

    By Alexandra Pecci • June 26, 2024
  • Moderna vax
    Image attribution tooltip
    Jens Schluete via Getty Images
    Image attribution tooltip
    Q&A

    Can Moderna’s COVID-flu combo shot improve flagging vaccination rates?

    A COVID and flu duo could ease manufacturing and administration, potentially driving higher vaccination rates, said Moderna’s VP of North American medical affairs.

    By June 25, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Ahead of its upcoming decision date, a competitor takes aim at KarXT

    The FDA isn’t slated to render a decision about BMS and Karuna’s potential breakthrough schizophrenia med until September — but a biotech is already hoping to be hot on its heels.  

    By Kelly Bilodeau • June 25, 2024